<DOC>
	<DOCNO>NCT00490490</DOCNO>
	<brief_summary>The purpose study assess response rate patient relapse refractory low-grade transform low-grade , CD20-positive , B-cell non-Hodgkin 's lymphoma Iodine-131 ( I-131 ) tositumomab ( Bexxar ) therapy plus local palliative radiation therapy ( XRT ) .</brief_summary>
	<brief_title>Study Bexxar &lt; Tositumomab &gt; Combined With External Beam Radiation Therapy</brief_title>
	<detailed_description>Response assess basis presence absence measurable lesion ≥ 1.4 x 1.4 cm ( operationally define ≥ 2.0 cm2 ) radiographic evaluation OR ≥ 1.0 cm great diameter detect palpation physical exam</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Lugol 's solution</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<criteria>INCLUSION CRITERIA Histologically confirm low grade CD20+ B cell nonHodgkin lymphoma ( NHL ) patient relapse chemotherapy chemotherapy resistant one sit disease measure 5 cm . The patient must fail least one chemotherapy regimen No anticancer treatment three week prior study initiation ( six week Rituximab , nitrosourea Mitomycin C ) Fully recover toxicity associate prior surgery , radiation , chemotherapy immunotherapy An institutional review board ( IRB ) approve sign inform consent Age 19 year old Expected survival least 6 month Prestudy Performance Status 0 , 1 2 accord World Health Organization ( WHO ) Absolute neutrophil count ( ANC ) least 1,500/mm³ Platelet count least 100,000/mm³ Hct &gt; 30 % Hgb &gt; 9.0 gm Bilirubin ≤ 2.0 Creatinine ≤ 2.0 Bone marrow involvement lymphoma le 25 % ( bilateral bone marrow ) within 6 week enrollment Acceptable birth control method men woman EXCLUSION CRITERIA Disease progression within 3 month last chemotherapy Prior myeloablative therapy bone marrow transplantation peripheral stem cell rescue Platelet count le 100,000/mm³ Hypocellular bone marrow ( ≤ 15 % cellularity ) Marked reduction bone marrow precursor one cell line History fail stem cell collection Prior treatment fludarabine Prior radioimmunotherapy Presence central nervous system ( CNS ) lymphoma HIV AIDSrelated lymphoma Evidence myelodysplasia bone marrow biopsy Abnormal bone marrow cytogenetics Patients receive prior external beam radiation therapy 25 % active bone marrow Patients receive filgrastim Sargramostim therapy within 3 week prior treatment Presence human antimouse antibody ( HAMA ) reactivity patient prior exposure murine antibody proteins Serious nonmalignant disease infection , , opinion investigator and/or sponsor , would compromise protocol objective Another primary malignancy ( squamous cell basal cell cancer skin , situ carcinoma cervix , treated prostate cancer stable prostatespecific antigen , PSA ) patient disease free least 3 year Major surgery , diagnostic surgery within 4 week Pleural effusion Pregnant Lactating</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>